Table 3 Univariable and multivariable analyses of the association between SP use and mutations in SP drug resistance genotypes by study period

dhfr triple mutant^a

 Use of SP in pregnancy‡

2.7 (1.0 to 7.5)

2.4 (0.8 to 7.1)

1.4 (0.634 to 3.0)

1.4 (0.6 to 3.2)

1.1 (0.3 to 3.3)

1.3 (0.4 to 4.7)

dhps double mutant^b

 Use of SP in pregnancy

3.5 (1.3 to 9.6)*

2.3 (0.7 to 7.0)

1.2 (0.3 to 4.1)

1.3 (0.3 to 5.2)

- ^f

- ^f

Combined dhfr/dhps^c,d

 Use of SP in pregnancy

4.2 (1.6 to 10.9) *

2.6 (0.9 to 7.4)

1.3 (0.6 to 2.6)

1.4 (0.7 to 2.9)

1.0 (0.3 to 2.9)

1.2 (0.3 to 4.1)